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Aprataxin,  aprataxin  and  PNKP-like  factor  (APLF)  and  polynucleotide  kinase  phosphatase  (PNKP)  are  key
DNA-repair  proteins  with  diverse  functions  but  which  all contain  a homologous  forkhead-associated
(FHA) domain.  Their  primary  binding  targets  are  casein  kinase  2-phosphorylated  forms  of the  XRCC1  and
XRCC4  scaffold  molecules  which  respectively  coordinate  single-stranded  and  double-stranded  DNA  break
repair pathways.  Here,  we  present  the  high-resolution  X-ray  structure  of  a  complex  of  phosphorylated
XRCC4  with  APLF,  the  most  divergent  of  the  three  FHA  domain  family  members.  This,  combined  withHA domain
NA break repair
NA-damage signalling
NMR  and  biochemical  analysis  of aprataxin  and  APLF  binding  to singly  and  multiply-phosphorylated
forms  of XRCC1  and  XRCC4,  and  comparison  with  PNKP  reveals  a pattern  of  distinct  but  overlapping
binding speciﬁcities  that  are  differentially  modulated  by multi-site  phosphorylation.  Together,  our  data
illuminate  important  differences  between  activities  of  the  three  phospho-binding  domains,  in spite  of  a
close evolutionary  relationship  between  them.
©  2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Genome integrity is under constant threat from a variety of
ndogenous and exogenous genotoxic agents, which create a
road spectrum of both single-stranded and double-stranded DNA
esions. Failure to repair such breaks can result in cell death
r tumor development. Several complex repair pathways have
volved to resolve various types of DNA lesions; these involve
tages of break detection, DNA end-processing, DNA gap ﬁlling
nd DNA ligation. XRCC1 is a crucial scaffolding protein in base
Abbreviations: APLF, aprataxin- and PNK-like factor; PNKP, polynucleotide
inase phosphatase; FHA, forkhead-associated; XRCC1, X-ray repair cross-
omplementing protein 1; XRCC4, X-ray repair cross-complementing protein 4;
ARP-1, poly(ADP-ribose)polymerase 1; NHEJ, non-homologous end-joining; DNA-
Kcs, catalytic subunit of DNA-dependent protein kinase; CK2, casein kinase 2; HIT,
istidine triad; ZF, zinc ﬁnger; NTD, N-terminal domain; BRCT, BRCA1 C-terminal;
C, coiled-coil; ITC, isothermal titration calorimetry; APTX, aprataxin.
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568-7864/© 2015 The Authors. Published by Elsevier B.V. This is an open access article uexcision repair that interacts with and coordinates many known
components of that pathway. These include poly(ADP-ribose) poly-
merase 1 (PARP-1) [1,2], polynucleotide kinase phosphatase (PNKP)
[3], aprataxin [4–8], aprataxin- and PNKP-like factor (APLF) [9,10],
DNA polymerase  [1,11] and DNA ligase III [12,13]. XRCC4 has
a parallel role in the non-homologous end-joining (NHEJ) pathway
for repair of double-stranded DNA breaks where it interacts with
the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs)
[14,15], PNKP [16], aprataxin [4], APLF [17,18] and DNA ligase IV
[19,20].
Whilst many of the repair pathway components bind to different
domains on the scaffolding proteins, three DNA-end modiﬁca-
tion proteins PNKP, aprataxin and APLF potentially compete for
the same binding sites on XRCC1 and XRCC4. PNKP has dual
activities; it phosphorylates 5′-OH termini and dephosphorylates
3′-phosphate termini which occur in >50% of breaks induced
by oxidative stress [21,22]. Aprataxin removes AMP  from 5′-
adenylated DNA which can be formed when DNA ligation is aborted
prematurely [23]. The precise role of APLF is yet to be deter-
mined although it does possess both endo- and exo-nuclease
activity and its depletion is associated with impairment of NHEJ
[18]. These three proteins share highly homologous forkhead-
associated (FHA) domains (Fig. 1A), which have been shown to
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Domain structure and CK2-phosphorylation sites of DNA repair proteins.
(A) Schematic representation showing forkhead-associated (FHA), histidine triad
(HIT), Ku-binding (KB), zinc ﬁnger (ZF), kinase and phosphatase domains of
aprataxin, APLF and PNKP. (B) Schematic representation of N-terminal (NTD),
BRCA1C-terminal (BRCT) and coiled-coil (CC) domains of XRCC1 and XRCC4 and
interspecies sequence conservation of CK2 sites. Positions of CK2-phosphorylation
sites in the core motif are denoted with yellow spheres and subsidiary CK2-sites
denoted with green spheres. Core motif residues conserved in both XRCC1 and
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volumes of protein and reservoir solution 0.1 M Tris pH 8.0, 30%RCC4 are highlighted in red and residues conserved within XRCC1 or XRCC4 are
ighlighted in light blue.
unction as protein–protein interaction modules through their
peciﬁc recognition of phosphothreonine-containing motifs on
nteracting partners [24–30]. All three bind XRCC1 and XRCC4
n a casein kinase 2 (CK2)-dependent manner [4,9,10,16–18,31].
omparison of CK2 sites in XRCC1 and XRCC4 reveals a common
xxSTDE core motif, in which both serine and threonine are phos-
horylated, with subsidiary sites present C-terminal to the core
otif (Fig. 1B). Both PNKP and aprataxin FHA domains can bind a
riphosphorylated peptide derived from this region of XRCC1 [7,32]
nd for PNKP each phosphate has been shown to contribute to bind-
ng afﬁnity. Here, we systematically investigate the role of each
f the XRCC1 and XRCC4CK2-phosphorylated residues in binding
f the aprataxin and APLF FHA domains. The crystal structure ofir 35 (2015) 116–125 117
the APLF FHA domain bound to a triphosphosphorylated XRCC4
peptide, together with NMR  titration experiments of aprataxin and
XRCC1 peptides are used to explore the structural basis for multi-
ple phospho-peptide binding. Together, these data reveal distinct
but overlapping binding modes and speciﬁcities for this important
family of DNA-damage responsive FHA domain proteins that are, in
turn, differentially regulated by multi-site phosphorylation of their
binding targets.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The genes for aprataxin residues 1–105 and APLF residues
1–106 were ampliﬁed using primer sets which incorporated 5′
BamHI and 3′ XhoI sites. PCR products and pGEX-6P-1 vector were
digested with BamHI and XhoI and religated. All point mutations
were generated using a QuickChange Site-Directed Mutagenesis Kit
(Stratagene) following the manufacturer’s recommended protocol.
For expression, the pGEX-6P-1/aprataxin-FHA constructs were
transformed into Escherichia coli strain BL21 (DE3) and the pGEX-
6P-1/APLF-FHA constructs transformed into the strain Rosetta2
(DE3). Cells were grown in LB at 37 ◦C to an A600 of 0.5, induced
with 0.4 mM isopropyl 1-thio--d-galactopyranoside and incu-
bated at 18 ◦C for a further 16 h before harvesting. Cells were lysed
by sonication and clariﬁed by centrifugation (20,000 × g × 30 min).
The supernatant was applied to a glutathione-4B resin (Amer-
sham) and cleaved from the resin with rhinovirus 3C protease.
Proteins were puriﬁed further by gel-ﬁltration chromatography on
a Superdex 75 matrix in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM
DTT. Selenomethionine-labelled APLF L91 M protein was expressed
in Rosetta2 (DE3) cells cultured in SelenoMet base media and nutri-
ents supplemented with seleno-methionine solution (Molecular
Dimensions Ltd.) and puriﬁed as the wild-type protein.
2.2. Isothermal titration calorimetry
Phosphopeptides based on the XRCC1 sequence
515-YAGSTDENTDSEEHQ-529 and the XRCC4 sequence 229-
YDESTDEES-237 were synthesised with amidated C-termini to
avoid potential end-effects of a free carboxy-terminus by Dr.  W.
Mawby (University of Bristol), puriﬁed by HPLC and characterised
by mass spectrometry. FHA-phosphopeptide binding was quanti-
ﬁed by isothermal titration calorimetry using a Microcal Omega
VP-ITC calorimeter (MicroCal Inc., Northampton, MA). Protein was
dialysed against ITC buffer (50 mM HEPES pH 7.5, 150 mM NaCl,
5 mM -mercaptoethanol) and peptides were dissolved in the
dialysis buffer. Experiments were carried out at 22 ◦C and involved
30 successive 10 l injections of peptide solution into a sample cell
containing protein solution. Titrations with XRCC1 peptides used
peptide at 1 mM and protein at 100 M and titrations with XRCC4
peptides used peptide at 300 m and protein at 30 M.  Heats of
dilution were subtracted and binding isotherms were plotted and
analysed with MicroCal origin version 7.0, assuming a single-site
binding model.
2.3. Crystallization and structure determination
Selenomethionine-labelled protein and peptide were combined
in a 1:3 ratio, with protein at a concentration of 10 mg/ml, in 50 mM
HEPES pH 7.5, 150 mM NaCl, 5 mM -mercaptoethanol. The com-
plex crystallised from hanging drops set up at 18 ◦C with equalw/v PEG 3350, 0.2 M MgCl2. Crystals grew within one week and
were transferred into cryoprotectant (50 mM  Tris pH 8.0, 15% w/v
PEG 3350, 0.1 M MgCl2, 75 mM NaCl, 25 mM HEPEs pH 7.5) and ﬂash
118 A.L. Cherry et al. / DNA Repa
Table 1
Crystallographic statistics.
Data collection APLF/XRCC4 SeMet
Space group P 212121
Cell dimensions
a, b, c (Å) 38.50 58.54 94.93
˛,  ˇ,  (◦) 90.0, 90.0, 90.0
Wavelength (Å) 0.98050
Resolution (Å) 30.0–1.38 (1.42–1.38)a
Rmergeb 5.3 (39.9)
I/ I 26.7 (3.7)
Completeness (%) 97.8 (80.4)
Redundancy 6.5 (5.1)
Reﬁnement
Resolution (Å) 28.0–1.38
No. reﬂections 43,936
Rworkc/Rfreed (%) 13.7/17.4
No. atoms
Protein 1736
Ligand/ion 147
Water 402
B-factors
Protein 14.5
Ligand/ion 26.3
Water 33.4
R.m.s deviations
Bond lengths (Å) 0.011
Bond angles (◦) 1.36
a Statistics for outer resolution shell.
b Rmerge =
∑
hkl
∑
i | Ii − I |/
∑
hkl
∑
Ii where Ii is the intensity of the ith
measurement of a reﬂection with indexes hkl and I is the statistically weighted
average reﬂection intensity.
c R-work =
∑
||Fo| − |Fc||/
∑
|Fo| where Fo and Fc are the observed and calculated
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d Rfree is the R-factor calculated with a random 5% of the reﬂections omitted from
eﬁnement.
rozen in liquid nitrogen. X-ray diffraction data were collected at
 single wavelength of 0.9805 Å on beamline I03 of the Diamond
ight Source using an ADSC CCD detector. A total of 720 images
ere collected with an oscillation angle of 1◦ and an exposure time
f 0.5 s per image. Data were integrated and scaled using DENZO
nd SCALEPACK [33] and SAD phasing and structure solution car-
ied out by the Autosol wizard of the PHENIX software package [34].
ubsequent reﬁnement was carried out at 1.4 Å using the PHENIX
eﬁne module of the PHENIX software package and manual model
uilding in Coot [35]. Data collection and reﬁnement statistics are
ummarised in Table 1. All structure ﬁgures were prepared with
yMol (http://www.pymol.org).
.4. NMR  spectroscopy
NMR  experiments were carried out at 22 ◦C on Bruker Avance
I+ 600 MHz  and Avance III 700 MHz  spectrometers, each equipped
ith a cryogenic triple-resonance probe. Protein and peptides
ere prepared in NMR  buffer (20 mM Na Acetate pH 5.8, 50 mM
aCl, 2 mM DTT). Three-dimensional HNCA, HNCO, HNCACB and
BCA(CO)NH experiments were performed to obtain backbone
ssignments. NMR  titration experiments were carried out by
dding the unlabelled XRCC1 peptides to 15N-labeled aprataxin
HA domain. The initial protein concentration was 92 M and
olumes of 2 mM stock solution of peptide were added until the
rotein:peptide ratio was 1:4. 1H-SOFAST-HMQC [36] spectra were
easured after each titration step. All spectra were processed
sing nmrPipe [37], and analysed using CARA/NEASY [38]. The
eighted chemical shift change (in ppm units) of each amide
roton (ıHN) and nitrogen (ıN) was calculated according to
he equation: ıtotal = [(ıHNWHN)2 + (ıNWN)2]1/2 with WHN = 1
nd WN = 0.154 [39]. Weighted chemical shifts for residues D37,
45, Q46, V61 and V63 were plotted against peptide concen-ir 35 (2015) 116–125
tration to determine individual Kds and averaged to determine
the apparent Kd.
3. Results
3.1. APLF and aprataxin FHA interactions with multi-phospho
forms of XRCC1 and XRCC4
APLF and aprataxin bind XRCC1 and XRCC4 following phospho-
rylation by CK2 on several clustered sites in both proteins. These
include the serine and threonine residues within a core heptapep-
tide sequence, YxxSTDE, found in both XRCC1 and XRCC4, as well
as subsidiary sites which lie C-terminal to the core motif and differ
between XRCC1 and XRCC4. We  used recombinant FHA domains
from aprataxin and APLF in isothermal titration calorimetry (ITC)
experiments with synthetic phosphopeptides to determine the
effects on binding of multiple phosphorylation of XRCC1 and XRCC4
within the core motif (Fig. 2A and B; Tables S1 and S2). APLF and
aprataxin can bind both XRCC1 and XRCC4 peptides phosphory-
lated solely on the threonine in the core motif (XRCC1 Thr519
and XRCC4 Thr233). For both FHA domains, binding to XRCC4 is
approximately 8-fold tighter than that to XRCC1. Serine is con-
served in the pT −1 position (i.e., one residue N-terminal to the
pThr) in both XRCC1 and XRCC4 in all species (Fig. 1B) an additional
phosphorylation of this serine improves binding in all cases by
factors of between 4- and 11-fold.
A third putative CK2 site is located C-terminal to the core motif
in the pT +4 position in both scaffolding proteins; Thr523 in XRCC1
and Ser237 in XRCC4. Additional phosphorylation at XRCC1 Thr523
marginally but reproducibly improves aprataxin binding by ∼3-fold
with a smaller effect observed for the addition of pSer237 in XRCC4.
In contrast, no signiﬁcant improvement in afﬁnity is observed for
APLF binding to either tri-phosphorylated peptide.
Human XRCC1 contains a fourth predicted CK2-site, Ser525 in
the pT +6 position, but phosphorylation of this residue does not
appreciably increase binding to either APLF or aprataxin. Of  the
CK2 sites identiﬁed in XRCC1 and XRCC4 outside the core motif,
only XRCC1 Thr523 (pT +4) is completely conserved across species
(Fig. 1B). In the light of this and our observation that XRCC1 Ser525
and XRCC4 Ser237 make no signiﬁcant contributions to APLF or
aprataxin FHA domain binding, the physiological signiﬁcance of
these two peripheral sites remains unclear.
Since FHA domains speciﬁcally recognise phosphothreonine
residues, we also tested binding to an XRCC1 peptide phospho-
rylated solely on the subsidiary Thr523 (Fig. 2C). Interestingly,
whereas aprataxin has a clear preference for binding to peptides
phosphorylated on the core threonine in XRCC1 rather than the
subsidiary one, APLF has approximately equal afﬁnity for both pep-
tides.
3.2. Structure of the APLF-XRCC4 complex
In order to determine the structural basis for improved bind-
ing of multiply-phosphorylated peptides to aprataxin and APLF,
weattempted to co-crystallise these FHA domains with XRCC1
and XRCC4-derived peptides. We were successful in growing
well diffracting crystals of the APLF FHA domain with a tri-
phosphorylated XRCC4 peptide. Neither the available structures
of PNKP FHA domain (PDB: 1UJX, 2BRF) nor that of aprataxin
(PDB:3KT9) proved useful for phasing of these X-ray data by molec-
ular replacement but we  were able to solve the structure using
the SAD method and crystals of selenomethionine-substituted pro-
tein and reﬁne against data extending to 1.4 Å resolution (Table 1).
The ﬁnal model contains two  complexes each comprising residues
1–104 of APLF with an additional ﬁve N-terminal-residues derived
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sothermal titration calorimetry of aprataxin (APTX) and APLF binding to peptides p
RCC1  sites (C). Results are representative of experiments performed in triplicate.
rom the cleaved GST-tag and the bound tri-phosphorylated XRCC4
hosphopeptide.
Comparison of the APLF FHA domain structure with those of
NKP [32] and aprataxin [40] shows that, as expected from the
elatively high degree of sequence homology, their FHA domain
-sandwich folds are similar overall (Fig. 3A), although, consistent
ith sequence comparison, the APLF structure is most divergent
nd contains a six-residue extension in loop 6–7.The overall structure of the peptide complex along with electron
ensity for the bound XRCC4 peptide is shown in Fig. 3B. The XRCC4
hosphopeptide adopts an orientation similar to that observed
n previously reported FHA/phosphopeptide structures [41], lyingn binding.
orylated on core CK2 XRCC1 sites (A), core CK2 XRCC4 sites (B) and subsidiary CK2
across the tips of loops 3–4 and 5–6. The core phosphothre-
onine is secured by a hydrogen-bonding network involving Arg27,
Ser39 and Arg40 (Fig. 3C). A second set of hydrogen bonds con-
strains the peptide backbone on either side; the Arg27 side-chain
interacts with the pT −2 and the Asn60 side-chain hydrogen-bonds
with the pT +1 carbonyl. Tyr229 in position pT −4 is held in place
by a hydrophobic stacking interaction with Pro29. Identical interac-
tions are present in structures of PNKP bound to an XRCC4 peptide
[42]. In accordance with the lack of binding effect associated with
phosphorylation of Ser237, only residues pT −4 to pT +2 could be
modelled into the electron density, indicating that the C-terminal
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Fig. 3. Structure of APLF-FHA:XRCC4 phosphopeptide complex.
(A) Sequence alignment and superposition of C backbone structures of the APLF FHA domain (red) aprataxin FHA domain (blue) PNKP FHA domain (grey). The positions of
-strands are indicated by arrows above the sequence alignment and the ﬁve residue insertion between 6-7 is boxed. (B) Ribbon representation showing the 10 -strands
as  red arrows with the molecular surface superimposed. Loops 3–4 and 5–6 involved in peptide binding are blue. Seven residues of an XRCC4-derived peptide are
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shown  in stick representation modeled into 2Fo-Fc density. The phosphothreonine b
he  FHA domain surface. (C) Schematic representation of protein-peptide contacts
aals interactions are denoted by red lines and green crescents respectively.
nd of the peptide, including Asp236 at pT +3, and pSer237 at the
T +4 position, is mobile.
.3. NMR  analysis of the aprataxin binding site
We  were not able to obtain crystals of aprataxin FHA in complex
ith any XRCC1 or XRCC4 phosphopeptide, but were able to use
olution NMR  to examine its interactions with various phosphory-
ated XRCC1 peptides. Triple-resonance experiments were used to
ssign the backbone chemical shifts of aprataxin and HMQC titra-
ion experiments with several XRCC1-derived peptides allowed
dentiﬁcation of the residues involved in binding by chemical-
hift perturbation. This information could then be related to ourn the canonical binding pocket whilst phosphoserine protrudes directly away from
en APLF FHA and triphosphorylated XRCC4 peptide. Hydrogen bonds and van der
previously determined X-ray structure of the aprataxin FHA
domain [40].
Spectra for titrations with core site mono- di- and tri-
phosphorylated XRCC1 peptides are essentially identical (Fig. 4A)
but allow us to estimate overall apparent afﬁnities of ∼7 M,
∼2 M and <1.0 M M for mono-, di- and tri-phosphorylated pep-
tides, respectively (Table S5). Although the afﬁnity constants for the
tighter binding peptides are not well deﬁned due to the high con-
centration of protein required for the NMR  experiment, they are,
nonetheless, broadly consistent with the additional contributions
of the second and third phosphosites measured by ITC. The major-
ity of residues exhibiting chemical shift changes were within loops
3–4 and 5–6 (Fig. 4B). Major shifts of the Arg29 and Ser41 NH
A.L. Cherry et al. / DNA Repair 35 (2015) 116–125 121
Fig. 4. Aprataxin phosphopeptide interactions.
(A) Selected chemical shifts from 1H [36] -SOFAST-HMQC spectra (22 ◦C) of 92 M aprataxin FHA domain, free (black) and in complex in a 1:4 ratio with XRCC1 peptides
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bAGSpTDENTDSEEHQ (red), YAGpSpTDENTDSEEHQ (green), YAGpSpTDENpTDSEEH
ositions are connected by black lines. (B) Predicted interactions between aprataxin
green  sphere). The FHA trace is colored on a blue to red scale to indicate the degre
esonances, the major pThr-interacting residues, conﬁrmed that
he peptide binding mode is similar to that generally observed in
ther FHA domain systems. In agreement with the APLF/XRCC4
rystal structure, the majority of shifts occur in residues that would
e predicted to interact with peptide positions N-terminal to the
Thr whilst, NH shifts for aprataxin residues equivalent to those
hat bind to the speciﬁcity-deﬁning peptide pT +3 position in non-
prataxin family FHA domains, are sparse or absent. Interestingly,
 similar set of residues was involved in chemical shift changes
ssociated with binding of the peptide solely phosphorylated on
he subsidiary threonine (K = 7.0 M),  indicating that it bindsdapp
ith the phosphothreonine in the canonical FHA domain phospho-
inding pocket rather than at a distinct site.rk blue) and YAGSTDENpTDSEEHQ (cyan). Free and the ﬁnal bound chemical shift
RCC1 peptides phosphorylated on the core-site (yellow sphere) and subsidiary site
emical shift movements in 1H [36] -SOFAST-HMQC titrations.
3.4. Structural basis of increased afﬁnity for pSpT forms of
XRCC1/4
The XRCC4 peptide contains acidic residues in positions pT −2,
pT −3, pT +1 and pT +2. The PNKP/XRCC4 complex suggests that
Arg44 provides electrostatic recognition of Glu pT −2 and Asp pT
+1 whilst Lys45 may  provide additional electrostatic recognition of
Asp pT +1 and Glu pT +2 [42]. APLF Arg37, equivalent to PNKP Lys45,
does not form any phosphopeptide interactions, instead assuming
a structural role through two salt bridges with Asp35 in the 3–4
loop of the FHA domain. Side-chain density for APLF Lys36, equiva-
lent to PNKP Arg44 is very poor suggesting that it is highly mobile.
However, it appears to be in a suitable position for electrostatic
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ecognition of both Glu pT −2, Asp pT +1 and pSer at pT −1 (see
elow).
The binding studies described above underline clearly the
ajor contribution of the primary pThr site in interactions with
oth XRCC1 and XRCC4. Of the remaining known phosphoryla-
ion sites within these motifs, the absolutely conserved pSer at pT
1 shows the greatest additional contribution to overall afﬁnity
f both aprataxin and APLF FHA domains for XRCC1 and XRCC4.
nterestingly, in the APLF/XRCC4 structure the pT −1 phosphoser-
ne assumes an upright, solvent exposed conformation, making
o direct contacts to FHA domain residues (Fig. 3B). By way
f comparison, the structure of PNKP FHA domain bound to a
ri-phosphorylated XRCC1 peptide shows two major conforma-
ions for the pT −1 phosphoserine of which the lower occupancy
onformation resembles that seen in the APLF/XRCC4 complex.
 second, higher occupancy conformer is involved in contacts
ith symmetry-related molecules and calcium ions in the lat-
ice but, nevertheless, makes substantial interactions with Arg48
rom the 3 to 4 loop. In our APLF complex, XRCC1 pSer518
s not constrained by crystal contacts but the electron density
s also suggestive of additional, low occupancy conformations.
mportantly, PNKP Arg48 is conserved in both APLF (Arg40) and
prataxin (Arg42), and APLF Arg40 and PNKP Arg48 adopt identi-
al positions in the respective peptide complex structures (Fig. 5A).
urthermore, from the APLF and PNKP structures of FHA domains
ound to multiply phosphorylated peptides, Lys36 in APLF, and its
tructurally equivalent residues Arg44 in PNKP, and Lys38 in
prataxin appear to be appropriately positioned for interaction
ith the pSer at the -1 position. Moreover, we have previously
hown that mutation of aprataxin Lys38 substantially reduces
inding to di-phosphorylated pSDpTD CK2 sites within the DNA-
amage mediator protein, Mdc1, where the additional serine
hosphorylation occurs at pT −2 [40]. We  therefore examined
he effects of mutating Arg42 and Lys38 on XRCC1 and XRCC4
eptide binding to aprataxin (Tables S3 and S4 respectively).
TC measurements showed that the aprataxin R42A mutation
everely compromised binding to all XRCC1 and XRCC4 pep-
ides, with an interpretable ITC signal only observable for di- and
ri-phosphorylated XRCC1. This presumably reﬂects loss of the
ubstantial interactions with the core pThr. Although these data
mphasise the importance of this residue in overall peptide bind-
ng, it is clearly impossible to discern any contribution of aprataxin
rg42 to the additional afﬁnity accrued from accessory serine phos-
horylation implied by the structural data. However, data from
he aprataxin K38A mutant were more illuminating and showed a
hree-fold decrease in binding to both monophosphorylated XRCC1
nd XRCC4 peptides (Fig. 5B). This is likely due to electrostatic
nteractions with Asp +1 that is present in both XRCC1 and XRCC4,
lthough additional contact with Glu -2 that is only found in XRCC4
ay  contribute in this particular complex. More importantly, we
oted that while the phosphorylation of Ser in the pT −1 posi-
ion increases wild-type aprataxin binding by ∼11-fold and 8-fold
o XRCC1 and XRCC4 respectively, the effect in the context of the
prataxin K38A mutant is signiﬁcantly reduced in both cases, sug-
esting that this residue contributes at least part of the increased
fﬁnity provided by the accessory Serine ‘-1’ phosphorylation.
. Discussion
PNKP, APLF and aprataxin contain closely related FHA domains,
hrough which they bind to XRCC1 and XRCC4 following phos-
horylation by CK2. In addition, we have previously shown that
prataxin associates through its FHA domain with diphospho-
ylated pSDpTD CK2 motifs in Mdc1 [40] that are also sites of
nteraction for the FHA and BRCT-repeat domains of the Nbs1 sub-ir 35 (2015) 116–125
unit of the Mre11/Rad50/Nbs1 complex [43]. Examination of CK2
sites in XRCC1 and XRCC4 reveals a common core YxxSTDE motif, in
which both serine and threonine are canonical CK2 sites, with one
or two  subsidiary sites C-terminal to this motif. The close prox-
imity of these sites suggests that more than one phosphate may
contribute to FHA domain binding. Indeed, studies of the PNKP
FHA domain have shown that mono- di- and tri- phosphorylated
XRCC1 peptides bind with progressively increasing afﬁnity [32].
Here we have investigated the interactions of XRCC1 and XRCC4
with the two other extant members of this atypical FHA domain
protein family, aprataxin and APLF, by a combination of structural
and biochemical approaches.
4.1. Multi-phosphorylation of XRCC1/4 differentially affects FHA
domain afﬁnity and speciﬁcity
We  have shown that APLF and aprataxin can bind XRCC1
and XRCC4 peptides phosphorylated solely on the core threonine
residue. Afﬁnity for XRCC4 is approximately 8-fold higher in both
cases and PNKP shows a similar, but less prominent preference
[16,32]. This consistently higher afﬁnity for XRCC4 over XRCC1 is,
most likely, due to the presence of additional acidic residues in
the pT −1 and pT −2 positions in XRCC4 that are absent in XRCC1
and which can form electrostatic interactions with the positively
charged binding surface characteristic of all three FHA domain
structures (see below).
As reported for PNKP/XRCC1 interactions [32], additional phos-
phorylation of Ser at the pT −1 position in the core motif of XRCC1 or
XRCC4 improves binding afﬁnity for both APLF and aprataxin. How-
ever, the increase in APLF binding to XRCC1 is less (∼3-fold) than for
all other combinations (7–11 fold). Furthermore, phosphorylation
of threonine in the pT +4 position of XRCC1 somewhat increases
binding afﬁnity for aprataxin and PNKP but not for APLF. These com-
bined effects mean that, in their triphosphorylated states, XRCC1
and XRCC4 bind to aprataxin with comparable afﬁnities whereas
binding of triphosphorylated XRCC1 to APLF is 26-fold weaker
than that of triphosphorylated XRCC4. Indeed, whilst the aprataxin
domain afﬁnities for both XRCC1 and XRCC4 are clearly inﬂu-
enced by pT +4 phosphorylation, APLF binding is not. Although
APLF has been implicated in repair of both single and double-
stranded breaks [10,18], the signiﬁcantly greater preference of APLF
for XRCC4 (Fig. 1B) suggests that its major biological role is in NHEJ
of double-stranded lesions, consistent with recent data [44]. Fur-
thermore, we  note that no combination of phosphorylations results
in favored binding of APLF for XRCC1 over XRCC4. Thus, APLF shows
a minimum preference for XRCC4 (deﬁned as Kd(XRCC1)/Kd(XRCC4))
of ∼2-fold up to a maximum of 26-fold for the triphosphorylated
species. In contrast, as with PNKP, aprataxin shows a range of speci-
ﬁcities depending on phosphorylation, which vary from a 121-fold
discrimination in favor of XRCC4 to a 5-fold preference for tri-
phospho XRCC1 over mono-phosphorylated (pT233) XRCC4. Thus,
our data suggest a mechanism for CK2-dependent modulation of
XRCC1/XRCC4 speciﬁcity through patterns of multi-site phospho-
rylation that decrease the discrimination of aprataxin between
these proteins whilst further increasing the preference of APLF for
XRCC4.
4.2. Surface basicity confers binding versatility
Interactions of APLF, aprataxin and PNKP FHA domains with
either XRCC1 or XRCC4 are additionally stabilized by approxi-
mately the same degree through phosphorylation of Ser-1. The
crystal structure of an APLF/triphosphorylated XRCC4 complex
showed this phosphoserine in the core motif to occupy a pre-
dominantly upright position facing directly away from the FHA
domain surface. This is in contrast to the PNKP/triphosphorylated
A.L. Cherry et al. / DNA Repair 35 (2015) 116–125 123
Fig. 5. Contribution of basic residues to phosphopeptide binding.
(A) Comparison of the electrostatic potential surfaces at the phosphopeptide-binding sites of the APLF, aprataxin (APTX) and PNKP FHA domains. The structure of the
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prataxin Lys38 mutation on XRCC1 and XRCC4 phosphopeptide binding. Binding is
ri-phosphorylated XRCC1 peptides and 3.2-, 7.6- and 9.3-fold respectively for XRC
RCC1 structure in which the phosphoserine assumes two con-
ormations; one upright and one bent over towards Arg44. NMR
itrations of the aprataxin FHA domain with a di-phosphorylated
eptide did not identify any interacting residues additional to those
mplicated in recognition of the mono-phosphorylated peptide.
onetheless, the greater effect of serine phosphorylation at the -1
osition on binding to wild-type compared with the K38A mutant
prataxin suggests a role in phosphoserine recognition. The equiva-
ent residue in APLF, Lys36, is also in a position to make electrostatic
nteractions with pSer-1, although a lack of density in our structure
mplies that it is rather mobile. Indeed, it may  be that this lack of
tructural order of aprataxin Lys38, APLF Lys36 and PNKP Arg44
nables recognition of pSer in either the -1 (pSpT; XRCC1/4) or -2
pSDpTD; Mdc1) positions in different binding partners. This over-
ll versatility appears to be a product of the general distribution of
asic side-chains on the FHA domains that are concentrated on the
urfaces that interact with the N-terminal residues of the XRCC1/4
inding motifs (Fig. 5). Interestingly, only aprataxin and PNKP
ave increased afﬁnity for triphosphorylated XRCC1 and XRCC4.
his may  be attributed to the extended basic surface provided by
prataxin Lys39 and PNKP Lys45 since the equivalent residue in
PLF, Arg37, is folded away from the surface. This surface differ-
nce may  also provide an explanation for observation of differing
bilities of these FHA domains to bind poly(ADP-ribose) [45].e of the isolated FHA [40] with that of the APLF complex (this study). (B) Effect of
ased relative to the wild-type 2.7-, 8.5 and 8.8- fold respectively for mono-, di- and
tides.
4.3. Aprataxin, APLF and PNKP assembly on
multi-phosphorylated XRCC1
Previous studies of the PNKP FHA domain showed that improved
binding afﬁnity observed with increased phosphorylation was
associated with the association of two FHA domains with each
of core (pS518/pT519) and subsidiary (pT523/pS525) sites within
a single XRCC1 peptide [32]. This led to the proposal of a coop-
erative mechanism in which binding of one FHA domain to the
core motif promotes binding at the subsidiary site. Our prelimi-
nary ITC observations showed that like PNKP, APLF and aprataxin
are also capable of binding an XRCC1 peptide phosphorylated solely
at Thr523 within the subsidiary site. Supporting NMR  titration
data further indicated that this peptide binds with the phospho-
threonine in the canonical binding pocket as might be predicted.
Nonetheless, an overall conservation of a ‘PNKP-like’ assembly
mode is not evident. Firstly, our data indicate that dimerisation of
the aprataxin FHA domain does not occur at all and inspection of
surface exposed residues on the 10-11 face of the -sandwich
suggest that Mdc1-like dimerization [46] is not possible (data not
shown) Secondly, although we did observe a reproducible increase
in stoichiometry for APLF with tri- and tetra-phosphorylated XRCC1
peptides suggestive of 2:1 binding, no indication of co-operativity
elicited through FHA–FHA interactions is evident. Indeed, more
recent binding experiments employing steady-state ﬂuorescence
methods have indicated a 1:1 stoichiometry for binding of PNKP
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HA to tetra-phosphorylated XRCC1 [47], more consonant with our
PLF and aprataxin data. The reasons for the apparent differences
etween the two PNKP studies remain unknown and will require
urther investigation.
. Conclusions
DNA damage generates a variety of different lesion types which
ach require the action of a particular array of DNA repair proteins.
he scaffolding proteins XRCC1 and XRCC4 recruit DNA-repair
odulators containing the aprataxin-family FHA domain to the
ites of damage through binding to CK2 phosphorylated sites. A
omplete understanding of the regulated recruitment of aprataxin,
PLF and PNKP will require further investigation of the interplay
etween their respective FHA-mediated interactions and other fac-
ors such as the involvement of additional binding domains and
atterns of post-translational modiﬁcation. To this end, we  have
ow shown how the FHA-mediated response of PNKP, aprataxin
nd APLF to differential phosphorylation of DNA-damage scaffolds
uch as XRCC1 and XRCC4 plays a major role in determining binding
electivity.
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